Citations

Clear

6273 citation(s) found for "To, Andrew".

Treatment with mTOR Inhibitors as primary immunosuppression after combined heart and kidney transplantation
Alnsasra, Hilmi , Akiki, Elias , Dean, Philip A. W. , Kushwaha, Sudhir S. , Asleh, Rabea , Khalil, Fouad , Briasoulis, Αlexandros , Dean, P, Bentall, Andrew

Mayo Clinic

European Heart Journal | October 28, 2024 | Volume: 45 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehae666.1135 Get It

Abstract Background It has been hypothesized that combined heart and kidney transplantation (HKT) may lead to immune modulation and attenuation of cardiac allograft vasculopathy (CAV) progression. Sirolimus (SRL) has been shown to mitigate the progression of CAV and confer renal protection. With the increasing use of SRL as primary immunosuppression in heart transplant (HT) recipients, the effect of HKT on CAV progression compared to HT-only remains undetermined. Purpose We sought to investigate the patterns of conversion from calcineurin inhibitors (CNI) to SRL, and its impact on CAV progression and outcomes in HKT compared to HT-only in a cohort with frequent use of SRL as primary immunosuppression. Methods A cohort of 302 patients who underwent either HT only (n=262) or combined HKT (n=40) was analyzed. CAV progression was assessed by measuring the delta (Δ) annual change in plaque volume (PV) normalized to vessel length (PV/VL in mm3/mm) and plaque index (PI) (%) (calculated as the PV to VV ratio) between baseline and last follow-up coronary intravenous ultrasound (IVUS). Clinical adverse outcomes included all-cause death and CAV-associated events. Secondary outcomes included differences in renal function and incidence of SRL-associated proteinuria (defined as Δ urine protein ≥300 mg/24 h at 1 year after conversion to SRL) between HT-only and HKT recipients. Results Overall, 217 (72%) patients were converted from CNI to SRL as primary immunosuppression. HT recipients were more likely to be converted to SRL than combined HKT recipients (74% vs. 55%, P=0.01). HKT was associated with significantly higher ΔPV/VL (P=0.01) and a trend toward a higher ΔPI (P=0.06) than HT-only, but this association was markedly attenuated after adjustment to SRL conversion. HKT was associated with similar risk of death (adjusted hazard ratio [HR] 0.69, 95%CI: 0.28-1.71, P=0.43) and CAV-related events (adjusted HR 0.83, 95% CI: 0.30-2.31, P=0.72). Conversion to SRL was significantly associated with decreased risk of death and CAV-related events in the overall cohort. This association was not modified by the type of organ transplantation (Pinteraction=NS), and without a significant effect on estimated glomerular filtration rate (eGFR) or proteinuria. Conclusions HKT recipients compared to HT-only were less likely to be converted from CNI to SRL-based immunosuppression and had a greater CAV progression but without significant differences in all-cause mortality or CAV-related events. The clinical benefit and safety of conversion to SRL appeared similar in the HKT and isolated HT cohorts.
Outcomes of bariatric surgery in obese patients with heart failure:a meta-analysis
Mangat, M M Manvir, Palicherla, Anirudh , Checketts, Thomas , Ellauzi, Rama , Elshaer, Ahmed , Dufani, Jalal, Aboeata, Ahmed, Anavekar, Nandan S., Ahmed, H, Ismayl, Mahmoud , Goldsweig, Andrew M.

Mayo Clinic

European Heart Journal | October 28, 2024 | Volume: 45 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehae666.1148 Get It

Abstract Background Patients with heart failure possess an increased risk for adverse outcomes with noncardiac surgery (1). While bariatric surgery is frequently performed in patients with obesity, there remains a limited understanding of the impact of bariatric surgery in obese patients with heart failure. Purpose The purpose of this study was to compare outcomes of bariatric surgery versus nonsurgical management in obese patients with heart failure. Methods We searched PubMed, EMBASE, and the Cochrane Library, through February 2024, for studies evaluating outcomes in obese patients with heart failure who underwent bariatric surgery compared to nonsurgical management. Outcomes assessed were postoperative atrial fibrillation, all-cause mortality, and hospital readmission. We used a fixed-effect model to calculate hazard ratios (HR) with 95% confidence intervals (CI) in R studio for outcomes assessed. In outcomes where significant heterogeneity was found (P< 0.05 and I2 > 60%), a random effects model was used. Results A total of 3 studies were identified, consisting of 260,186 patients. Compared to nonsurgical management, bariatric surgery was associated with a significant reduction in postoperative atrial fibrillation (HR 0.72; 95% CI: 0.62-0.84), all-cause mortality (HR 0.50; 95%CI 0.35-0.72), and hospital readmission (HR 0.73; 95% CI 0.69-0.78) in obese patients with heart failure. Conclusion Our study suggests that bariatric surgery significantly reduces post-operative atrial fibrillation, mortality, and hospital readmission among obese patients with heart failure.Our findings demonstrate that bariatric surgery should be considered as a viable intervention in obese patients with heart failure. Further studies are warranted to confirm our findings.Forest Plots of Outcomes Assessed
Serial changes in left atrial strain in symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten: insights from VALOR-HCM trial
Desai, Milind Y. , Wolski, Kathy , Owens, Amanda, Geske, Jeffrey B. , Saberi, Sima, Cremer, Paul , Lakdawala, Neal K. , Tower‐Rader, Albree, Fermin, Damian , Naidu, Suveeksha, Lampl, Kathy, Sehnert, Amy J. , Fermin, David , Geske, Jeffrey B , Cremer, Paul C , Fermin, David , Okushi, Yuichiro , Popovic, Zoran B , Owens, A, Wang, Andrew , Fermin, D

Mayo Clinic

European Heart Journal | October 28, 2024 | Volume: 45 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehae666.013 Get It

Abstract Background In severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), the VALOR-HCM phase 3 randomized, double-blind, placebo-controlled clinical trial demonstrated that mavacamten, a cardiac myosin inhibitor, reduces the eligibility for septal reduction therapy with sustained improvement in left ventricular (LV) outflow tract gradients and symptoms. Mavacamten also resulted in favorable cardiac remodeling, including improvement in left atrial volume index (LAVI), LV diastolic function, and biomarkers (NT-proBNP and troponin T). However, the impact of mavacamten on LA function is not known. Objective We sought to assess serial changes in LA strain measures in patients enrolled in the VALOR-HCM trial. Methods VALOR-HCM included 112 symptomatic obstructive HCM patients (mean age 60 years, 51% male). Patients assigned to mavacamten at baseline (n=56) continued therapy for 56 weeks and those assigned to placebo crossed over to mavacamten (n=52) from week 16-56 (40-week exposure). Echocardiographic LA strain assessment was performed according to the current American and European guideline recommendations, using a vendor-neutral post processing software. For assessment of LA strain components (reservoir, conduit, and contraction), the non-foreshortened apical 4-chamber view was utilized. The zero reference was set at end-diastole. Results Serial changes in LAVI and all components of mean LA strain from baseline to week 56 are shown in the Figure. At baseline, LAVI and all mean LA strain values were worse than reported normal mean thresholds. There was a continued and significant improvement in all 3 LA strain values, from baseline to week 56, along with a significant reduction in LAVI. Improvement in LAVI was seen earlier than improvements in LA strain. There was a significant inverse correlation between change in mean LAVI and LA reservoir strain from baseline to week 56 (r= -0.42, p<0.001). Conclusions In the VALOR-HCM trial, average LAVI and baseline LA strain values were significantly worse than reported normal thresholds. Treatment with mavacamten resulted in an improvement in LAVI and LA strain values from baseline through week 56 suggesting a sustained favorable impact on cardiac remodeling. The advantageous cardiac remodeling associated with long-term treatment with mavacamten may in turn have a favorable impact on the observed high burden of atrial tachyarrhythmias in HCM.Serial changes in LA strain in VALOR-HCM
Biomarkers of cardiohepatic syndrome in the cardiac intensive care unit
Butt, Abid, Crespo‐Diaz, Ruben , Katz, Jason N. , Kamath, Priyanka , Miller, Erin , Rosenbaum, Andrew , Butt, A, Padkins, Mitchell , Hillerson, Dustin , Kamath, P, Miller, E, Samsky, Marc D. , Kashani, Kianoush , Jentzer, Jacob C.

Mayo Clinic

European Heart Journal | October 28, 2024 | Volume: 45 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehae666.1742 Get It

Abstract Introduction Non-cardiovascular end-organ dysfunction is an important determinant of outcomes in cardiac intensive care unit (CICU) patients. We examined the association between in-hospital mortality with the severity and extent of admission liver function test (LFT) abnormalities in a heterogeneous CICU population. Purpose We hypothesized that a greater severity or extent of LFT abnormalities would be associated with higher in-hospital mortality. Methods We included consecutive unique adult CICU patients with available data for one or more of the admission LFT values of interest. Admission laboratory values were defined as those closest to CICU admission. We used the NIH Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 to categorize the severity of each LFT abnormality from Grade 0 (normal) to Grade 4 (life-threatening). We defined the extent of LFT abnormality as the number of individual LFTs meeting criteria for CTCAE Grade 1 or greater. The primary outcome of interest was all-cause in-hospital mortality. Odds ratio (OR) and 95% confidence interval (CI) values for in-hospital mortality were estimated using logistic regression, before and after multivariable adjustment. Results Of 12,428 unique CICU patients, 5,144 were excluded due to a lack of available data for any admission LFT values. The remaining 7,284 patients comprised the final study population. Among patients with available data for each individual LFT, abnormal values were present in: AST, 2,743/5,733 (47.8%); ALT 1,576/5,512 (28.6%); ALK 611/3,684 (16.6%); and TB 898/5,155 (17.4%). A total of 864 (11.9%) patients died during hospitalization. In-hospital mortality was higher for patients with one or more LFTs meeting criteria for CTCAE Grade 1 or greater (17.9% vs. 6.4%, adjusted OR 1.54 [1.27-1.86], p <0.001). A stepwise increase in in-hospital mortality was observed with increasing CTCAE grade, both overall (adjusted OR 1.25 per each higher CTCAE grade [1.16-1.34], p <0.001); (Figure 1A), and for each individual LFT (Figure 1B). Conclusion Cardiohepatic syndrome is an important predictor of prognosis in CICU patients, as the extent and severity of LFT abnormalities are strongly associated with in-hospital mortality. This is the first large-scale study to examine the association between the magnitude of hepatic biomarker derangement with in-hospital mortality in unselected CICU patients. Patients with markedly elevated LFT values exhibited the highest risk of in-hospital mortality. This analysis advocates for the inclusion of commonly obtained LFTs in future risk-prediction tools for enhanced prognostication.
Diagnosis and Management of Thoracolumbar Spinal Disorders Presenting as Cardiac, Gastrointestinal, and Other False Pain Syndromes
Brown, Nolan J. , Kuo, Cathleen C. , Pennington, Zach , Choi, Ashley E. , Chan, Andrew K. , Bui, Nicholas, Pham, Martin H. , Oh, Michael , Pennington, Zach , Zhang, Angie , Shahrestani, Shane , Hatter, Matthew J. , Camino-Willhuber, Gaston O

Mayo Clinic

Clinical Spine Surgery | October 25, 2024 | Volume: 38 | Issue: 3 | Pages: 114-122

10.1097/bsd.0000000000001644 | PMID 39450872 Get It

Summary of Background Data: Although pseudoangina is most commonly caused by cervical disc herniation, several cases have been described where thoracic herniation produced symptoms of pseudoangina. If thoracic herniation can produce angina-like pain, then it is important to consider whether pathology of the thoracolumbar spine, in general, can trigger false pain syndromes distinct from pseudoangina. Objective: We seek to provide the most comprehensive study regarding the diagnosis and treatment of spinal conditions causing false pain syndromes. Study Design: Systematic review of the current literature using PRISMA 2020 recommendations. Methods: We queried the literature and systematically selected relevant studies according to PRISMA guidelines. Results: Across 22 selected studies, the sample size was 30 patients, and a total of 26 met the criteria for statistical analysis. Seven (26.9%) of these patients presented with a chief complaint of pseudoangina resulting from thoracic disc herniation. 73.1% (19/26) of patients exhibited pain mimicking visceral origin. Overall, 13/19 (68.4%) patients exhibited thoracic spine disease only and 4/19 (21.1%) patients were affected at lumbar levels only, while 2 (10.5%) patients exhibited thoracolumbar herniation. Presentations included abdominal pain (11/19) mimicking appendicitis or pancreatitis, flank pain mimicking renal colic (8/19), and 2 cases of scrotal pain/orchalgia. Symptom durations ranged from acute (<24 h) to 7 years. Treatments were reported for 18/19 patients and all treated patients reported alleviated pain. Seven out of 18 patients were managed conservatively while 11/18 were treated surgically. Misdiagnosis resulted in unnecessary surgery (pancreaticojejunostomy) or other invasive procedures. Conclusions: In spinal disorders manifesting with atypical pain syndromes, delay in proper diagnosis and unnecessary treatments can, unfortunately, cause prolonged patient suffering and increased cost of health care. As a result, some have proposed that spinal screening should be incorporated into clinical examinations involving false pain syndromes.
Outcomes of ST-Segment Elevation Myocardial Infarction in Patients With Adrenal Insufficiency
Abdallah, N. Ben , Abdallah, Meriam , Abdallah, Nadhem , Mohamoud, Abdilahi , Ismayl, Mahmoud , Aronow, Herbert D. , Goldsweig, Andrew M.

Mayo Clinic

Journal of the Endocrine Society | October 25, 2024 | Volume: 8 | Issue: 12 | Pages: No page available

10.1210/jendso/bvae186 | PMID 39569135 Get It

Abstract Context Patients with adrenal insufficiency (AI) have both increased risk of cardiovascular disease and adverse outcomes with many medical emergencies. However, limited data exist specifically regarding ST-segment elevation myocardial infarction (STEMI) in the context of AI. Objective To evaluate associations between AI and in-hospital outcomes of patients with STEMI. Methods Admissions for STEMI were identified in the 2016-2019 National Inpatient Sample. In-hospital outcomes were compared between patients with and without AI. The primary outcome was in-hospital mortality. Secondary outcomes included percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG), intervention, acute kidney injury (AKI), vasopressor use, mechanical circulatory support (MCS), mechanical ventilation, ventricular tachycardia (VT), hospital length of stay (LOS), and total charges. Multivariable regression models were used to adjust for potential confounders. Results Among 690 430 STEMI hospitalizations, 1382 (0.2%) had a diagnosis of AI. AI was associated with higher odds of in-hospital mortality (adjusted OR [aOR] 1.51, 95% CI 1.03-2.2), lower odds of PCI (aOR 0.73, 95% CI 0.55-0.98), higher odds of CABG (aOR 2.8, 95% CI 1.89-4.2) and, AKI (aOR 2.38, 95% CI 1.72-3.3), VT (aOR 1.55, 95% CI 1.1-2.2), need for vasopressors (aOR 2.34, 95% CI 1.33-4.1), mechanical ventilation (aOR 2.11, 95% CI 1.54-2.89), and MCS (aOR 2.18, 95% CI 1.57-3.03). Patients with AI also had a longer LOS (10 days vs 4.2 days, P &lt; .001) and higher charges ($258 475 vs $115 505, P &lt; .001). Conclusion Patients with AI admitted for STEMI had higher in-hospital mortality, nonfatal adverse outcomes, and resource utilization than patients without AI.
Novel risk loci in LGI1-antibody encephalitis: genome-wide association study discovery and validation cohorts
Elliott, Katherine S. , Gilbert, Edmund , Harper, Andrew R. , Sempere, Vicente Peris, Pinto, Anne‐Laurie , Rayner, N. William, Mentzer, Alexander J. , Delanty, Norman, Picard, Géraldine , Titulaer, Maarten J. , Kuhlenbäeumer, Gregor, Mignot, Emmanuel , Cavelleri, Gianpiero L, Irani, Sarosh R. , Cavalleri, Gianpiero L. , Mentzer, Alexander J , Handel, Adam , Melzer, Nico , Lee, Soon-Tae , Leypoldt, Frank , Honnorat, Jérôme , Mignot, Emmanuel , Irani, Sarosh R , Cavalleri, Gianpiero L , Titulaer, Maarten J , Binks, Sophie , Muñiz‐Castrillo, Sergio , Araujo, Tânia Kawasaki de , Brown, Andrew , Chong, Amanda Yoon-Yee , Band, Gavin , Costantino, Félicie , Rogemond, Véronique , Handel, Adam E. , Lee, Soon‐Tae , Honnorat, Jérôme , Knight, Julian Charles

Mayo Clinic

Brain | October 24, 2024 | Volume: 148 | Issue: 3 | Pages: 737-745

10.1093/brain/awae349 | PMID 39454566 Get It

Abstract Encephalitis with antibodies to leucine-rich glioma-inactivated 1 (LGI1-Ab-E) is a common form of autoimmune encephalitis, presenting with seizures and neuropsychiatric changes, predominantly in older males. More than 90% of patients carry the human leukocyte antigen (HLA) class II allele, HLA-DRB1*07:01. However, this is also present in 25% of healthy controls. Therefore, we hypothesized the presence of additional genetic predispositions. In this genome-wide association study and meta-analysis, we studied a discovery cohort of 131 French LGI1-Ab-E and a validation cohort of 126 American, British and Irish LGI1-Ab-E patients, ancestry-matched to 2613 and 2538 European controls, respectively. Outside the known major HLA signal, we found two single nucleotide polymorphisms at genome-wide significance (P &lt; 5 × 10−8), implicating PTPRD, a protein tyrosine phosphatase, and LINC00670, a non-protein coding RNA gene. Meta-analysis defined four additional non-HLA loci, including the protein coding COBL gene. Polygenic risk scores with and without HLA variants proposed a contribution of non-HLA loci. In silico network analyses suggested LGI1 and PTPRD-mediated interactions via the established receptors of LGI1, ADAM22 and ADAM23. Our results identify new genetic loci in LGI1-Ab-E. These findings present opportunities for mechanistic studies and offer potential markers of susceptibility, prognostics and therapeutic responses.
S136 Obesity Is Associated With Worsened Endoscopic Outcomes in Patients With Pancreatic Collections and Should Be Integrated Into the QNI Classification
Baroud, Serge , Annan, Karim Al , Mrad, Rudy , Han, Sam , Law, Ryan , Bofill-García, Aliana, Martin, John A. , Petersen, Bret T. , Vege, Santhi Swaroop , Kerbage, Anthony , AbiMansour, Jad P. , Vargas, Eric J. , Storm, Andrew C. , Chandrasekhara, Vinay , Petersen, Bret T. , Bazerbachi, Fateh , Majumder, Shounak , Dayyeh, Barham K. Abu

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S102-S103

10.14309/01.ajg.0001028912.11285.a9 Get It

S2096 Influence of Insulin Dosage on Type 2 Diabetes Remission After Metabolic and Bariatric Surgery: A Comparative Analysis of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy
Salameh, Yara , Abboud, Donna Maria , Ghanem, Omar M. , Abboud, Donna M , Ghusn, Wissam , Salameh, Yara , Mosleh, Kamal Abi , Shah, Mithun V , Storm, Andrew C. , Dayyeh, Barham K. Abu

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S1497-S1498

10.14309/01.ajg.0001037752.22295.4b Get It

S1978 Plasma High-Resolution Metabolomics Identifies Differences in Linoleic Acid and Vitamin A Metabolism Between Adults With Steatosis and Steatohepatitis
Gawey, Brent J. , Comba, Yagmur Y., Ziegler, Thomas R. , Neish, Andrew S. , Cave, Matt, Smith, Matthew Ryan , Jones, Dean P.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S1415-S1415

10.14309/01.ajg.0001037280.36964.59 Get It